Brazil's AI MedTech Firewall: Pure Global on Cracking ANVISA's Surprise Cybersecurity Mandate

Last week, Brazil's regulatory landscape for MedTech was redefined. ANVISA, the national health agency, unexpectedly rolled out a stringent new framework mandating advanced cybersecurity and data privacy compliance for all AI-driven medical devices. This sudden move disrupts market-entry plans and forces an immediate re-evaluation of regulatory strategies for companies targeting Latin America's largest market. This episode dives deep into the practical consequences of this new regulation. We break down the specific documentation now required, from threat modeling to LGPD compliance, and analyze why simply leveraging your existing FDA or CE Mark approval is no longer a viable path to market access in Brazil. **Key Questions Answered in This Episode:** * What are the specific cybersecurity protocols ANVISA now demands for AI-enabled devices? * How does this new regulation intersect with Brazil's data protection law, the LGPD? * Why is my existing international documentation suddenly insufficient for a Brazilian submission? * What is the single biggest risk for MedTech startups trying to navigate this new rule? * How can this regulatory hurdle be turned into a competitive advantage? * What immediate steps should your company take to de-risk your market entry plan for Brazil? * Are there any "hidden" requirements in the new resolution that could delay your launch? Don't let regulatory hurdles block your access to the vibrant LATAM market. Pure Global combines local expertise with AI-powered data tools to streamline your path to compliance and success. From market access strategy to local representation, we offer end-to-end solutions for MedTech and IVD innovators. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.